Drug
buntanetap/posiphen
buntanetap/posiphen is a pharmaceutical drug with 5 clinical trials. Currently 2 active trials ongoing. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
2(40%)
Results Posted
100%(2 trials)
Phase Distribution
Ph phase_2
3
60%
Ph phase_3
2
40%
Phase Distribution
0
Early Stage
3
Mid Stage
2
Late Stage
Phase Distribution5 total trials
Phase 2Efficacy & side effects
3(60.0%)
Phase 3Large-scale testing
2(40.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
5
all time
Status Distribution
Active(3)
Completed(2)
Detailed Status
Completed2
Active, not recruiting1
Recruiting1
Not yet recruiting1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
2
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 23 (60.0%)
Phase 32 (40.0%)
Trials by Status
active_not_recruiting120%
completed240%
recruiting120%
not_yet_recruiting120%
Recent Activity
2 active trials
Showing 5 of 5
not_yet_recruitingphase_2
An Open-label Long-term Safety Study of Buntanetap in Participants With AD
NCT07757204
recruitingphase_2
A Study of Buntanetap in Participants With PD
NCT07284784
active_not_recruitingphase_3
A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD
NCT06709014
completedphase_2
A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD
NCT05686044
completedphase_3
A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD
NCT05357989
Clinical Trials (5)
Showing 5 of 5 trials
NCT07757204Phase 2
An Open-label Long-term Safety Study of Buntanetap in Participants With AD
NCT07284784Phase 2
A Study of Buntanetap in Participants With PD
NCT06709014Phase 3
A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD
NCT05686044Phase 2
A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD
NCT05357989Phase 3
A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5